VERAXA Biotech (NASDAQ: VRXA) is implementing New Approach Methodologies (NAMs) across its preclinical research programs, a strategic shift that could significantly enhance the predictive value of its early-stage cancer drug testing while addressing growing regulatory and ethical pressures to reduce animal use. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., announced the move on October 7, 2026, positioning itself among a wave of drug developers adopting human-relevant testing techniques that include cell-based assays, computational modeling, and three-dimensional spheroid cultures.
The implications of this announcement extend beyond animal welfare. By aligning its research with FDA-supported NAMs, VERAXA aims to generate data that more accurately reflects how its drug candidates will behave in humans, potentially reducing the high failure rates that plague oncology drug development. The company’s lead programs—BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates—are designed to treat cancer by harnessing the immune system and delivering targeted payloads to tumor cells. More predictive preclinical models could help VERAXA prioritize the most promising candidates and design more efficient clinical trials.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, the company required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. VERAXA says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This dramatic reduction in animal use—roughly 95% fewer mice—demonstrates the practical efficiency of the NAMs approach, which could lower research costs and shorten timelines while satisfying increasing regulatory expectations for human-relevant data.
For investors, the announcement signals VERAXA’s commitment to a differentiated research strategy that may improve the odds of clinical success for its antibody-based pipeline. The company’s focus on human-relevant testing also aligns with broader industry trends, as regulators and payers increasingly demand evidence that preclinical findings translate to patient benefit. MissionIR, a communications platform focused on enhancing visibility for private and public companies, highlighted the news through its MissionIR network, noting that further details are available in the company’s newsroom at https://ibn.fm/VRXA. The announcement was also covered by Read More>>.
VERAXA’s move comes as part of a broader ecosystem of investor-focused communications. MissionIR operates as part of the Dynamic Brand Portfolio at IBN, which provides wire distribution through InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. Such channels help companies like VERAXA reach a wide audience of investors and journalists, amplifying the impact of strategic announcements. For VERAXA, the expanded use of NAMs could be a key differentiator as it seeks to advance its BiTAC candidates toward clinical development, where human-relevant data may carry more weight with regulators and partners.
